Cellular Membrane-Derived Nanovesicles Expressing hCD64 for Targeting Prostate Cancer
Sehan Kim1, Jeonghyeon Lee1, Jaesung Park1,2
1School of Interdisciplinary Bioscience and Bioengineering (I-Bio), Pohang University of Science and Technology (POSTECH), Pohang, Gyeong-buk 37673, Republic of Korea.
ACS Applied Bio Materials
|September 24, 2024
Summary
Engineered nanovesicles targeting prostate cancer show promise. By incorporating human Fcγ receptor I (hCD64), these bleb nanovesicles enhance targeting and reduce clearance, offering a potential new platform for cancer therapy.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Extracellular vesicles are promising therapeutic agents but suffer from poor targeting and rapid clearance by phagocytes, necessitating high doses and leading to adverse effects.
- Current limitations of extracellular vesicles hinder their clinical application, particularly in targeted cancer therapies.
- Prostate cancer exhibits a specific membrane antigen, presenting an opportunity for targeted therapeutic strategies.
Purpose of the Study:
- To develop enhanced nanovesicles with improved targeting capabilities for prostate cancer therapy.
- To overcome the limitations of natural extracellular vesicles, including poor targeting and rapid clearance.
- To investigate the potential of Fcγ receptor-I (hCD64)-expressing nanovesicles for targeted delivery of anti-prostate-specific membrane antigen (PSMA) antibodies.
Main Methods:
- Development of bleb nanovesicles engineered to express human Fcγ receptor I (hCD64).
- Conjugation of anti-prostate-specific membrane antigen (PSMA) antibodies to the hCD64-expressing nanovesicles.
- In vitro validation using PSMA-related prostate cancer cell lines.
- In vivo assessment in prostate cancer xenograft mouse models.
Main Results:
- hCD64-expressing bleb nanovesicles demonstrated successful binding to PSMA-related cell lines.
- Targeting ability of the engineered nanovesicles was confirmed in vivo within prostate cancer xenograft models.
- The nanovesicle platform showed potential for enhanced drug delivery and reduced clearance.
Conclusions:
- Fcγ receptor-IgG-conjugated nanovesicles represent a viable platform for targeted cancer therapy.
- This approach offers a promising strategy to overcome the limitations of traditional extracellular vesicle-based therapies.
- Further research into nanovesicle Fcγ receptor-IgG systems could advance cancer diagnosis and treatment systems.
